Navigation Links
NOV in Biological Technology

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

...S EST), Level 2, West Hall C. The poster entitled " P h ase I e val u ation of orally-ad m inistered CYT997, a nov e l cytotoxic vascular- d isrupting agent, in patients with advanced cance r " details safety, tolerability and pre...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

...onths, which compares very favorably with historical data (Brundage Can J Oncol. 1996 Feb; 6 Suppl 1:25-32.; Bezjak Int J Radiat Oncol Biol Phys. 2002 nov 1;54(3):719-28; Sundstrom J Clin Oncol. 2004 Mar 1;22(5):801-10). "Numerous NSCLC patients undergo radiotherapy because they are unfit for radical c...

/C O R R E C T I O N -- Rosetta Genomics Ltd/

... In the news release, "Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference" issued on 5 nov 2008 13:30 GMT, by Rosetta Genomics Ltd nasdaq:ROSG over PR Newswire, we are advised by a representative of the company that new webcast information h...

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

...uloxetine 60-120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome. Poster presented at the American College of Rheumatology Annual Meeting; nov 2007, Boston, MA. (5) Chappell, AS, et al. A 1-Year Safety and Efficacy Study of Duloxetine in Patients with Fibromyalgia. Poster presented at Europ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

...clinic/ta/gist/gist1.htm 7. Gleevec(R) (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; nov 2007. Media Contacts Media only: Kim Fox, Novartis Oncology, P: +1 862 778 7692 Dana Kahn Cooper, P: +1 732 817 1800, C: +1 732 239 6664 Inve...

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

...udy. Blood, Feb 2008. 3. Gleevec(R) (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; nov 2007. Media Contacts Media Only: Kim Fox Novartis Oncology P: +1 862 778 7692 C: +1 917 415 2425 Dana Kahn Cooper P: +1 732 817 1800 C: +1...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

..., Education and Welfare, 1976 9. "Introduction," Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement 1998 nov 16-18; 16(2): 1-37. Available at: http://consensus.nih.gov/1998/1998AttentionDeficitHyperactivityDisorder11 0html.htm Accessed on May 7, 2007 (...

FDA Accepts Ranexa(R) sNDA and NDA for Filing

... PALO ALTO, Calif., nov 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the U.S. Food and Drug Administration (FDA) has notified the ...

BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet

...://www.signplus.com/company Contact: Softpro GmbH, Joerg-M. Lenz, jle@softpro.de , Mobile: +49-160-4788-512, at the show in Las Vegas from nov 13 - 15 Wilhelmstrasse 34, 71034 Boeblingen, Germany ...

Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

...is as follows: 2007 Financial Guidance as of as of as of (dollars in millions) Jan 4, 2007 Jul 26, 2007 nov 1, 2007 VELCADE U.S. net sales $240 - 260 $250 - 260 $~265 Royalties $140 - 150 $150 - 155 $~160 ...

Oragene is compatible with TaqMan SNP genotyping

... Trends Genet. 14, 266272. 3. Technical Bulletin: DNA Quantification Using the Fluorescence/DNase (F/D) Assay, v1.2. DNA Genotek. nov 29, 2004. 4. TaqMan SNP Genotyping Assays Protocol. Part Number 4332856 Rev. B. Applied Biosystems. June, 2004. back...

Oragene and Whole Genome Amplification with GenomiPhi

... Biotech. 21(12): 531-535. 2. Technical Bulletin: DNA Quantification Using the Fluorescence/DNase (F/D) Assay, v1.2. DNA Genotek. nov 29, 2004. 3. TaqMan SNP Genotyping Assays Protocol. Part Number 4332856 Rev. B. Applied Biosystems. June, 2004. 4. Tec...
Other Tags
(Date:7/23/2014)... disease, the devastating neurological disease affecting more than ... new progress on a set of compounds, initially ... a potential oral therapy for Alzheimer,s. Their study ... . , Carlo Ballatore, Kurt R. Brunden and ... protein known as tau binds to and stabilizes ...
(Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
(Date:7/23/2014)... is available in German . ... Max Planck Institute of Molecular Cell Biology and ... capture detailed three-dimensional images of cardiac dynamics in ... Plane Illumination Microscopy (SPIM) and clever image processing ... heart. Furthermore, they have developed a method of ...
Breaking Biology News(10 mins):Unbreak my heart 2
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... Adipic acid is an intermediate chemical ... plastic, often referred to as engineering thermoplastics. These ... the monomers employed. Due to the high production ... increasing number of developing countries, the Asia-Pacific region ... by Europe and North America. Adipic acid in ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Children and teens who lose ... death in adulthood, a new study suggests. People who ... 50 percent greater risk of death during the study period ... parent, according to the report. Although the study found ... risk of premature death, it wasn,t designed to prove cause-and-effect. ...
(Date:7/23/2014)... ill patients arriving at the emergency department, the ... amnesia for rapid, life-saving intubation, despite decades-old studies ... results of a systematic review of 10 recent ... a "wonder drug" are published online in ... of Ketamine on Intracranial and Cerebral Perfusion Pressure ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
Other Contents